|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.10.25 - 21:03
|
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder (GlobeNewswire EN)
|
|
|
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY® (risperidone) as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder (BD-I) in adults. The approval is based on existing clinical data for UZEDY, coupled with Model-Informed Drug Development (MIDD) methodologies that leverage previous findings on the safety and efficacy of risperidone formulations already approved for BD-I....
|
|
|
10.10.25 - 13:03
|
TEVA Pharmaceutical Aktie: Stabile Q3-Aussichten (Aktiencheck)
|
|
|
Charlotte (www.aktiencheck.de) - TEVA Pharmaceutical-Aktienanalyse von BofA Securities:
Bank of America (BofA) habe das Kursziel für die Aktie von TEVA Pharmaceutical Industries Ltd. (ISIN: US8816242098, WKN: 883035, Ticker-Symbol: TEV, NYSE-Symbol: TEVA) von 22 auf 24 USD erhöht und das "buy"-Rating bekräftigt. [mehr]...
|
|
|
10.10.25 - 13:02
|
TEVA Pharmaceutical Aktie: Stabile Q3-Aussichten, Kaufvotum bestätigt (Aktiencheck)
|
|
|
Petach TikvaCharlotte (www.aktiencheck.de) - TEVA Pharmaceutical-Aktienanalyse von BofA Securities:
Bank of America (BofA) habe das Kursziel für die Aktie von TEVA Pharmaceutical Industries Ltd. (ISIN: US8816242098, WKN: 883035, Ticker-Symbol: TEV, NYSE-Symbol: TEVA) von 22 auf 24 USD erhöht und das "buy"-Rating bekräftigt. [mehr]...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
